ND0612 clinical trials
Also written ND0612.
How each study uses ND0612 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses ND0612 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease PatientsCompletedPhase 2NeuroDerm Ltd.NCT01883505Written as ND0612
- A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's DiseaseActive, not recruitingPhase 2NeuroDerm Ltd.NCT02726386Written as ND0612
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor FluctuationsActive, not recruitingPhase 3NeuroDerm Ltd.NCT04006210Written as ND0612 Solution for SC infusion
- A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) PatientsCompletedPhase 1NeuroDerm Ltd.NCT01725802Written as Levodopa/carbidopa solution for SC administration
- A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease PatientsCompletedPhase 1NeuroDerm Ltd.NCT02096601Written as LD/CD SC solution
- A Sequential Two-Part, Open-Label Study in Healthy Male and Female SubjectsCompletedPhase 1NeuroDerm Ltd.NCT02604914Written as ND0612
- A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's DiseaseCompletedPhase 2NeuroDerm Ltd.NCT02577523Written as ND0612 (Levodopa/Carbidopa solution)
- A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsWithdrawnPhase 3NeuroDerm Ltd.NCT02782481Written as ND0612
- A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral SuspensionWithdrawnPhase 3NeuroDerm Ltd.NCT03462043Written as ND0612